Royal Marsden Hospital
Sutton, Surrey SM25NG
4 studies enrolling now · 27 studies all time
What they study most
Acute Myeloid Leukemia, Adenovirus, Advanced Cancer, Advanced Cholangiocarcinoma, Advanced Solid Tumor, Advanced Solid Tumor and Lymphoma Malignancies, Biliary Tract Cancer, Brain Cancer, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Chronic Lymphocytic Leukemia, Cutaneous Squamous Cell Cancer
Studies at this site
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors — Recruiting now
- A Study of Sigvotatug Vedotin in Advanced Solid Tumors — Recruiting now
- Study of HLD-0915 in Patients With Metastatic Prostate Cancer — Recruiting now
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) — Recruiting now
- Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma — Recruiting now
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer — Running, not enrolling
- Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma — Completed
- Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) — Running, not enrolling
- NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) — Completed
- Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations — Stopped early
- A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency — Completed
- An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) — Completed
- First in Human Study of M4344 in Participants With Advanced Solid Tumors — Completed
- An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas — Completed
- A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies — Completed
- A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer — Completed
- A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer — Completed
- A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer — Completed
- The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation — Stopped early
- Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) — Completed
- Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer — Completed
- A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer — Completed
- A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer — Completed
- Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) — Completed
- An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene — Completed
- An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene — Completed
- Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma — Completed